EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial

Liselotte Tas, Marie B Weitemeyer, Maartje W Rohaan, Troels H Borch, Alexander C J van Akkooi, Michel W J M Wouters iD, Koen J Hartemink, Yvonne M Schrage iD, Anke Kuijpers, Niels F M Kok, Maaike van Zon, Inge Jedema und 13 weitere

British Journal of Surgery · 2025

DOI: 10.1093/bjs/znaf090 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift British Journal of Surgery, 2025. Verfasst von Liselotte Tas und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Melanoma, Lymphocytes, Tumor-Infiltrating, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: The Dutch Cancer Society, Netherlands Organisation for Health Research and Development, Dutch Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this study was to describe the impact of surgical resections on tumour-infiltrating lymphocyte (TIL) therapy, based on results from a randomized phase III trial comparing TIL therapy with standard ipilimumab in patients with metastatic melanoma (NCT02278887).

Methods

Surgical details of all operations performed in the trial were collected. Location, total number, and size of resected metastases were assessed in relation to successful TIL investigational medicinal product (IMP) manufacture and response to TIL therapy.

Results

A total of 93 operations were needed to treat 80 patients with TIL therapy. Surgical complications were detected in 17% of operations. These were mostly mild Clavien–Dindo grade I/II complications and one Clavien–Dindo grade IIIa complication. The size or number of resected lesions did not significantly impact the TIL-IMP manufacture failure or response rate. The failure rate of TIL-IMP manufacture from lymph node metastases was 2.8% (1 of 36), which was lower than from subcutaneous metastases (19.4% (6 of 31), P = 0.037) and other sites (15.0% (3 of 20), P = 0.038). Response rates per resected lesion type were 52.9% (18 of 34) for lymph nodes, 40.9% (9 of 22) for subcutaneous lesions, 58.8% (10 of 17) for other lesions, and 60.0% (3 of 5) for combinations of lesions, without statistically significant differences.

Conclusion

Tumour resections for TIL-IMP manufacture lead to limited surgical complications. Manufacture with a therapeutic response was successful using lesions of varying sizes from different anatomical locations, with highest rates for lymph nodes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaLymphocytes, Tumor-InfiltratingSkin NeoplasmsHumansFemaleMaleMiddle AgedIpilimumabAgedAdultTreatment OutcomeAntineoplastic Agents, ImmunologicalPostoperative ComplicationsLymphatic Metastasis

Substanzen

IpilimumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Plastic Surgery, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
  • Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Division of Radiotherapy, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • National Centre for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
  • Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Michel W J M Wouters, Yvonne M Schrage, Winan J van Houdt

Förderung

  • The Dutch Cancer Society
  • Netherlands Organisation for Health Research and Development
  • Dutch Ministry of Health
  • Stichting Avento
  • Antoni van Leeuwenhoek Foundation
  • Copenhagen University Hospital
  • Danish Cancer Society
  • Capital Region of Denmark

Zitieren

APA

Tas, L., Weitemeyer, M. B., Rohaan, M. W., Borch, T. H., van Akkooi, A. C. J., Wouters, M. W. J. M., Hartemink, K. J., Schrage, Y. M., Kuijpers, A., Kok, N. F. M., van Zon, M., Jedema, I., Nijenhuis, C. M., Nuijen, B., Hansen, M., Voermans, C., Klobuch, S., Seijkens, T. T. P., Lalezari, F., …, & van Houdt, W. J. (2025). Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial. British Journal of Surgery. https://doi.org/10.1093/bjs/znaf090

Vancouver

Tas L, Weitemeyer MB, Rohaan MW, Borch TH, van Akkooi ACJ, Wouters MWJM, et al. Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial. British Journal of Surgery. 2025. doi:10.1093/bjs/znaf090

BibTeX
@article{Tas2025,
  author = {Tas, Liselotte and Weitemeyer, Marie B and Rohaan, Maartje W and Borch, Troels H and van Akkooi, Alexander C J and Wouters, Michel W J M and Hartemink, Koen J and Schrage, Yvonne M and Kuijpers, Anke and Kok, Niels F M and van Zon, Maaike and Jedema, Inge and Nijenhuis, Cynthia M and Nuijen, Bastiaan and Hansen, Marten and Voermans, Carlijn and Klobuch, Sebastian and Seijkens, Tom T P and Lalezari, Ferry and Met, Özcan and Donia, Marco and Svane, I Marie and Haanen, John B A G and Hölmich, Lisbet R and van Houdt, Winan J},
  title = {Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial},
  journal = {British Journal of Surgery},
  year = {2025},
  doi = {10.1093/bjs/znaf090}
}
Kostenlos starten →